Back to mobile site

Seattle Genetics (SGEN) Weakness Creates Buying Opportunity, Says Analyst

May 2, 2014 1:28 PM EDT Send to a Friend
H.C. Wainwright reiterated a Buy rating on Seattle Genetics (NASDAQ: SGEN) with a price target of $65. Analyst Andrew S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login